78 related articles for article (PubMed ID: 19743858)
1. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
Das SG; Doshi JM; Tian D; Addo SN; Srinivasan B; Hermanson DL; Xing C
J Med Chem; 2009 Oct; 52(19):5937-49. PubMed ID: 19743858
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
3. Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy.
Das SG; Hermanson DL; Bleeker N; Lowman X; Li Y; Kelekar A; Xing C
ACS Chem Biol; 2013 Feb; 8(2):327-35. PubMed ID: 23102022
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
Das SG; Srinivasan B; Hermanson DL; Bleeker NP; Doshi JM; Tang R; Beck WT; Xing C
J Med Chem; 2011 Aug; 54(16):5937-48. PubMed ID: 21780800
[TBL] [Abstract][Full Text] [Related]
5. Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis.
Doshi JM; Tian D; Xing C
Mol Pharm; 2007; 4(6):919-28. PubMed ID: 17874842
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
Aridoss G; Zhou B; Hermanson DL; Bleeker NP; Xing C
J Med Chem; 2012 Jun; 55(11):5566-81. PubMed ID: 22582991
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Hermanson DL; Das SG; Li Y; Xing C
Mol Pharmacol; 2013 Aug; 84(2):236-43. PubMed ID: 23696245
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 1. Structure-activity relationships of the 4-aryl group.
Kemnitzer W; Drewe J; Jiang S; Zhang H; Wang Y; Zhao J; Jia S; Herich J; Labreque D; Storer R; Meerovitch K; Bouffard D; Rej R; Denis R; Blais C; Lamothe S; Attardo G; Gourdeau H; Tseng B; Kasibhatla S; Cai SX
J Med Chem; 2004 Dec; 47(25):6299-310. PubMed ID: 15566300
[TBL] [Abstract][Full Text] [Related]
9. A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML.
Bleeker NP; Cornea RL; Thomas DD; Xing C
Mol Pharm; 2013 Nov; 10(11):4358-66. PubMed ID: 24079514
[TBL] [Abstract][Full Text] [Related]
10. 4H-Chromene-based anticancer agents towards multi-drug resistant HL60/MX2 human leukemia: SAR at the 4th and 6th positions.
Puppala M; Zhao X; Casemore D; Zhou B; Aridoss G; Narayanapillai S; Xing C
Bioorg Med Chem; 2016 Mar; 24(6):1292-7. PubMed ID: 26867486
[TBL] [Abstract][Full Text] [Related]
11. CXL146, a Novel 4
Bian T; Tagmount A; Vulpe C; Vijendra KC; Xing C
Mol Pharmacol; 2020 Jun; 97(6):402-408. PubMed ID: 32276963
[TBL] [Abstract][Full Text] [Related]
12. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.
Manero F; Gautier F; Gallenne T; Cauquil N; Grée D; Cartron PF; Geneste O; Grée R; Vallette FM; Juin P
Cancer Res; 2006 Mar; 66(5):2757-64. PubMed ID: 16510597
[TBL] [Abstract][Full Text] [Related]
13. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
14. ITH4012 (ethyl 5-amino-6,7,8,9-tetrahydro-2-methyl-4-phenylbenzol[1,8]naphthyridine-3-carboxylate), a novel acetylcholinesterase inhibitor with "calcium promotor" and neuroprotective properties.
Orozco C; de Los Rios C; Arias E; León R; García AG; Marco JL; Villarroya M; López MG
J Pharmacol Exp Ther; 2004 Sep; 310(3):987-94. PubMed ID: 15111641
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in-vitro cytotoxicity of poly-functionalized 4-(2-arylthiazol-4-yl)-4H-chromenes.
Mahmoodi M; Aliabadi A; Emami S; Safavi M; Rajabalian S; Mohagheghi MA; Khoshzaban A; Samzadeh-Kermani A; Lamei N; Shafiee A; Foroumadi A
Arch Pharm (Weinheim); 2010 Jul; 343(7):411-6. PubMed ID: 20309872
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 4-aryl-4H-chromenes as a new series of apoptosis inducers using a cell- and caspase-based HTS assay. Part 5: modifications of the 2- and 3-positions.
Kemnitzer W; Jiang S; Wang Y; Kasibhatla S; Crogan-Grundy C; Bubenik M; Labrecque D; Denis R; Lamothe S; Attardo G; Gourdeau H; Tseng B; Drewe J; Cai SX
Bioorg Med Chem Lett; 2008 Jan; 18(2):603-7. PubMed ID: 18077161
[TBL] [Abstract][Full Text] [Related]
17. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
[TBL] [Abstract][Full Text] [Related]
18. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
[TBL] [Abstract][Full Text] [Related]
19. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
Ganguly A; Basu S; Banerjee K; Chakraborty P; Sarkar A; Chatterjee M; Chaudhuri SK
Mol Biosyst; 2011 May; 7(5):1701-12. PubMed ID: 21409205
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.
Bacherikov VA; Chou TC; Dong HJ; Zhang X; Chen CH; Lin YW; Tsai TJ; Lee RZ; Liu LF; Su TL
Bioorg Med Chem; 2005 Jun; 13(12):3993-4006. PubMed ID: 15911312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
